|
1
|
Spath C, Nitsche U, Muller T, Michalski C,
Erkan M, Kong B and Kleeff J: Strategies to improve the outcome in
locally advanced pancreatic cancer. Minerva Chir. 70:97–106.
2015.PubMed/NCBI
|
|
2
|
Waddell N, Pajic M, Patch AM, Chang DK,
Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, et al:
Whole genomes redefine the mutational landscape of pancreatic
cancer. Nature. 518:495–501. 2015.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Balachandran VP, Luksza M, Zhao JN,
Makarov V, Moral JA, Remark R, Herbst B, Askan G, Bhanot U,
Senbabaoglu Y, et al: Identification of unique neoantigen qualities
in long-term survivors of pancreatic cancer. Nature. 551:512–516.
2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Russo AA, Tong L, Lee JO, Jeffrey PD and
Pavletich NP: Structural basis for inhibition of the
cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a.
Nature. 395:237–243. 1998.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Schlitter AM, Segler A, Steiger K,
Michalski CW, Jäger C, Konukiewitz B, Pfarr N, Endris V,
Bettstetter M, Kong B, et al: Molecular, morphological and survival
analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs):
Identification of prognostic subtypes. Sci Rep.
7(41064)2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:1039–1049.
2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Attri J, Srinivasan R, Majumdar S, Radotra
BD and Wig J: Alterations of tumor suppressor gene p16INK4a in
pancreatic ductal carcinoma. BMC Gastroenterol.
5(22)2005.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ohtsubo K, Watanabe H, Yamaguchi Y, Hu YX,
Motoo Y, Okai T and Sawabu N: Abnormalities of tumor suppressor
gene p16 in pancreatic carcinoma: Immunohistochemical and genetic
findings compared with clinicopathological parameters. J
Gastroenterol. 38:663–671. 2003.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Moskaluk CA, Hruban RH and Kern SE: p16
and K-ras gene mutations in the intraductal precursors of human
pancreatic adenocarcinoma. Cancer Res. 57:2140–2143.
1997.PubMed/NCBI
|
|
10
|
Sellers WR, Rodgers JW and Kaelin WG Jr: A
potent transrepression domain in the retinoblastoma protein induces
a cell cycle arrest when bound to E2F sites. Proc Natl Acad Sci
USA. 92:11544–11548. 1995.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Caldas C, Hahn SA, da Costa LT, Redston
MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ and Kern
SE: Frequent somatic mutations and homozygous deletions of the p16
(MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 8:27–32.
1994.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Schutte M, Hruban RH, Geradts J, Maynard
R, Hilgers W, Rabindran SK, Moskaluk CA, Hahn SA, Schwarte-Waldhoff
I, Schmiegel W, et al: Abrogation of the Rb/p16 tumor-suppressive
pathway in virtually all pancreatic carcinomas. Cancer Res.
57:3126–3130. 1997.PubMed/NCBI
|
|
13
|
Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP,
Hruban RH and Goggins M: Hypermethylation of multiple genes in
pancreatic adenocarcinoma. Cancer Res. 60:1835–1839.
2000.PubMed/NCBI
|
|
14
|
Oshima M, Okano K, Muraki S, Haba R, Maeba
T, Suzuki Y and Yachida S: Immunohistochemically detected
expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4)
strongly predicts survival in patients with resectable pancreatic
cancer. Ann Surg. 258:336–346. 2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Masetti M, Acquaviva G, Visani M, Tallini
G, Fornelli A, Ragazzi M, Vasuri F, Grifoni D, Di Giacomo S,
Fiorino S, et al: Long-term survivors of pancreatic adenocarcinoma
show low rates of genetic alterations in KRAS, TP53 and SMAD4.
Cancer Biomark. 21:323–334. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Jeong J, Park YN, Park JS, Yoon DS, Chi HS
and Kim BR: Clinical significance of p16 protein expression loss
and aberrant p53 protein expression in pancreatic cancer. Yonsei
Med J. 46:519–525. 2005.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Larque AB, Conde L, Hakim S, Alos L, Jares
P, Vilaseca I, Cardesa A and Nadal A: P16(INK4a)
overexpression is associated with CDKN2A mutation and worse
prognosis in HPV-negative laryngeal squamous cell carcinomas.
Virchows Arch. 466:375–382. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhao W, Huang CC, Otterson GA, Leon ME,
Tang Y, Shilo K and Villalona MA: Altered p16(INK4) and RB1
expressions are associated with poor prognosis in patients with
nonsmall cell lung cancer. J Oncol. 2012(957437)2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lam AK, Ong K, Giv MJ and Ho YH: p16
expression in colorectal adenocarcinoma: Marker of aggressiveness
and morphological types. Pathology. 40:580–585. 2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Milde-Langosch K, Bamberger AM, Rieck G,
Kelp B and Loning T: Overexpression of the p16 cell cycle inhibitor
in breast cancer is associated with a more malignant phenotype.
Breast Cancer Res Treat. 67:61–70. 2001.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yachida S, White CM, Naito Y, Zhong Y,
Brosnan JA, Macgregor-Das AM, Morgan RA, Saunders T, Laheru DA,
Herman JM, et al: Clinical significance of the genetic landscape of
pancreatic cancer and implications for identification of potential
long-term survivors. Clin Cancer Res. 18:6339–6347. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cancer Genome Atlas Research Network.
Electronic address: uriandrew_aguirre@dfci.harvard.edusimpleandrew_aguirre@dfci.harvard.edu;
Cancer Genome Atlas Research Network: Integrated genomic
characterization of pancreatic ductal adenocarcinoma. Cancer Cell
32: 185-203.e13, 2017.
|
